Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors
IHE offers lower costs and higher income through a concentrated play on established drugmakers, while IBB provides broader exposure to 243 biotech firms with higher volatility.
Full story
Read the full story at The Motley Fool ↗
Continue reading this story on The Motley Fool, the publisher that reported it.
AI tools
Written by AI from the article text. It can make mistakes; check the original story.
